Repare Therapeutics Inc. (RPTX): Price and Financial Metrics


Repare Therapeutics Inc. (RPTX): $13.61

0.28 (+2.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RPTX POWR Grades


  • Value is the dimension where RPTX ranks best; there it ranks ahead of 39.75% of US stocks.
  • The strongest trend for RPTX is in Stability, which has been heading down over the past 163 days.
  • RPTX ranks lowest in Momentum; there it ranks in the 4th percentile.

RPTX Stock Summary

  • RPTX's went public 1.59 years ago, making it older than just 2.84% of listed US stocks we're tracking.
  • RPTX's price/sales ratio is 663.97; that's higher than the P/S ratio of 99.24% of US stocks.
  • As for revenue growth, note that RPTX's revenue has grown 185.05% over the past 12 months; that beats the revenue growth of 95.93% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Repare Therapeutics Inc, a group of peers worth examining would be FUSN, IDYA, FULC, LPTX, and VXRT.
  • To check out Repare Therapeutics Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001808158.

RPTX Valuation Summary

  • In comparison to the median Healthcare stock, RPTX's EV/EBIT ratio is 141.98% lower, now standing at -12.3.
  • Over the past 15 months, RPTX's price/earnings ratio has gone up 22.1.
  • RPTX's price/earnings ratio has moved up 22.1 over the prior 15 months.

Below are key valuation metrics over time for RPTX.

Stock Date P/S P/B P/E EV/EBIT
RPTX 2021-08-31 2175.9 5.1 -16.4 -12.3
RPTX 2021-08-30 2143.8 5.1 -16.2 -12.1
RPTX 2021-08-27 2159.1 5.1 -16.3 -12.2
RPTX 2021-08-26 2109.8 5.0 -15.9 -11.9
RPTX 2021-08-25 2229.7 5.3 -16.9 -12.7
RPTX 2021-08-24 2174.5 5.1 -16.4 -12.3

RPTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RPTX has a Quality Grade of D, ranking ahead of 8.52% of graded US stocks.
  • RPTX's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RPTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -4.742
2021-03-31 0.001 1 -4.174
2020-12-31 0.000 1 -4.813

RPTX Price Target

For more insight on analysts targets of RPTX, see our RPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $47.63 Average Broker Recommendation 1.45 (Moderate Buy)

RPTX Stock Price Chart Interactive Chart >

Price chart for RPTX

RPTX Price/Volume Stats

Current price $13.61 52-week high $40.00
Prev. close $13.33 52-week low $13.18
Day low $13.61 Volume 1,045
Day high $13.61 Avg. volume 181,910
50-day MA $21.03 Dividend yield N/A
200-day MA $28.48 Market Cap 568.01M

Repare Therapeutics Inc. (RPTX) Company Bio


Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.


RPTX Latest News Stream


Event/Time News Detail
Loading, please wait...

RPTX Latest Social Stream


Loading social stream, please wait...

View Full RPTX Social Stream

Latest RPTX News From Around the Web

Below are the latest news stories about Repare Therapeutics Inc that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022

Repare Therapeutics highlights key milestones expected in 2022 (NASDAQ:RPTX)

Repare Therapeutics (RPTX) provides key milestones anticipated in 2022.Initiation of a monotherapy Phase 2 TRESR trial of RP-3500, for the treatment of solid tumors with…

Seeking Alpha | January 7, 2022

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

CAMBRIDGE, Mass. & MONTREAL, January 07, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.

Yahoo | January 7, 2022

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

CAMBRIDGE, Mass. & MONTREAL, January 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.

Yahoo | January 5, 2022

Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL, January 03, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.

Yahoo | January 3, 2022

Read More 'RPTX' Stories Here

RPTX Price Returns

1-mo N/A
3-mo -41.06%
6-mo -60.72%
1-year -63.90%
3-year N/A
5-year N/A
YTD -35.47%
2021 -38.51%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8281 seconds.